Biosimilars : Current Situation And Future Prospects, Worldwide

Navi Mumbai, India (PressExposure) March 26, 2012 -- The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with the vast majority of leading originator brands in the global biologics market expected to lose some degree of protection by 2019. All major countries now make provision for an abbreviated biosimilar development and regulatory pathway. Funds are flowing into the sector and many new partnership agreements signed. Everything in the biosimilar garden might look rosy, but what is the reality?

Biosimilar sales of $16+ billion were forecast in the EU and US alone for 2011.This estimate turned out to be 50-times too high. Does publication of the long-awaited guidance on the US Biologics Price Competition and Innovation Act mean a new dawn for biosimilars, or another false one? Written with the understandable detail and objectivity you need, Biosimilars: Current Situation & Future Prospects, Worldwide provides the answers, including: Market Research Companies

- On the basis of several years market experience in Europe and Japan, where and with which biosimilars has most and least success been achieved, and why.

- Complexities of biological patents.

- The big controversies with biosimilars explained: Sourcing of reference products, similarity, naming, interchangeability, immunogenicity, traceability, indication extrapolation.

- Where payers incentivise usage of biosimilars.

- The importance of devices to administer biosimilars.

- Which companies are most active in biosimilar development, what are their targets and how far have they reached.

- Where biosimilar prospects are brightest through 2016

* Comprehensive: From patents/data exclusivity via development, manufacturing issues to regulatory requirements, pricing and reimbursement demands, funding provisions and beyond to the realities of the market - it's all here

* Global: The situation in 27 developed and developing countries - across Europe, the Americas, Asia-Pacific and the Indian subcontinent

* Up-to-date: Includes 2011 sales data and February 2012 proposed FDA guidance

* Fact-filled: Over 60 tables

Executive Summary

1. Introduction


Rationale for biosimilars

Regulatory guidelines

Types of biosimilars

Lack of standardisation

Market situation

2. Safety Concerns

Issues with biosimilars

Issues with originator products





Scare stories

For more information kindly visit :

Biosimilars : Current Situation & Future Prospects, Worldwide


Bharat Book Bureau

Tel: +91 22 27810772 / 27810773

Fax: + 91 22 27812290



Follow us on twitter:!/Sandhya3B

About Bharat Book Bureau

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.

Press Release Source:

Press Release Submitted On: March 26, 2012 at 3:33 am
This article has been viewed 8100 time(s).